Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Jul 1;357(Pt 1):263–268. doi: 10.1042/0264-6021:3570263

Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data.

A Cortés 1, M Cascante 1, M L Cárdenas 1, A Cornish-Bowden 1
PMCID: PMC1221950  PMID: 11415458

Abstract

The concentration of an inhibitor that decreases the rate of an enzyme-catalysed reaction by 50%, symbolized i(0.5), is often used in pharmacological studies to characterize inhibitors. It can be estimated from the common inhibition plots used in biochemistry by means of the fact that the extrapolated inhibitor concentration at which the rate becomes infinite is equal to -i(0.5). This method is, in principle, more accurate than comparing the rates at various different inhibitor concentrations, and inferring the value of i(0.5) by interpolation. Its reciprocal, 1/i(0.5), is linearly dependent on v(0)/V, the uninhibited rate divided by the limiting rate, and the extrapolated value of v(0)/V at which 1/i(0.5) is zero allows the type of inhibition to be characterized: this value is 1 if the inhibition is strictly competitive; greater than 1 if the inhibition is mixed with a predominantly competitive component; infinite (i.e. 1/i(0.5) does not vary with v(0)/V) if the inhibition is pure non-competitive (i.e. mixed with competitive and uncompetitive components equal); negative if the inhibition is mixed with a predominantly uncompetitive component; and zero if it is strictly uncompetitive. The type of analysis proposed has been tested experimentally by examining inhibition of lactate dehydrogenase by oxalate (an uncompetitive inhibitor with respect to pyruvate) and oxamate (a competitive inhibitor with respect to pyruvate), and of cytosolic malate dehydrogenase by hydroxymalonate (a mixed inhibitor with respect to oxaloacetate). In all cases there is excellent agreement between theory and experiment.

Full Text

The Full Text of this article is available as a PDF (176.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barlow R. B., Bond S. M., Bream E., Macfarlane L., McQueen D. S. Antagonist inhibition curves and the measurement of dissociation constants. Br J Pharmacol. 1997 Jan;120(1):13–18. doi: 10.1038/sj.bjp.0700865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brandt R. B., Laux J. E., Yates S. W. Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. Biochem Med Metab Biol. 1987 Jun;37(3):344–349. doi: 10.1016/0885-4505(87)90046-6. [DOI] [PubMed] [Google Scholar]
  3. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  4. Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J. 1974 Jan;137(1):143–144. doi: 10.1042/bj1370143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cortes A., Emery D. C., Halsall D. J., Jackson R. M., Clarke A. R., Holbrook J. J. Charge balance in the alpha-hydroxyacid dehydrogenase vacuole: an acid test. Protein Sci. 1992 Jul;1(7):892–901. doi: 10.1002/pro.5560010707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DIXON M. The determination of enzyme inhibitor constants. Biochem J. 1953 Aug;55(1):170–171. doi: 10.1042/bj0550170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DOWD J. E., RIGGS D. S. A COMPARISON OF ESTIMATES OF MICHAELIS-MENTEN KINETIC CONSTANTS FROM VARIOUS LINEAR TRANSFORMATIONS. J Biol Chem. 1965 Feb;240:863–869. [PubMed] [Google Scholar]
  8. Hesse L. M., Venkatakrishnan K., Court M. H., von Moltke L. L., Duan S. X., Shader R. I., Greenblatt D. J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000 Oct;28(10):1176–1183. [PubMed] [Google Scholar]
  9. Klatt P., Cacho J., Crespo M. D., Herrera E., Ramos P. Nitric oxide inhibits isoproterenol-stimulated adipocyte lipolysis through oxidative inactivation of the beta-agonist. Biochem J. 2000 Oct 15;351(Pt 2):485–493. [PMC free article] [PubMed] [Google Scholar]
  10. Law P. Y., Kouhen O. M., Solberg J., Wang W., Erickson L. J., Loh H. H. Deltorphin II-induced rapid desensitization of delta-opioid receptor requires both phosphorylation and internalization of the receptor. J Biol Chem. 2000 Oct 13;275(41):32057–32065. doi: 10.1074/jbc.M002395200. [DOI] [PubMed] [Google Scholar]
  11. Lerche C., Seebohm G., Wagner C. I., Scherer C. R., Dehmelt L., Abitbol I., Gerlach U., Brendel J., Attali B., Busch A. E. Molecular impact of MinK on the enantiospecific block of I(Ks) by chromanols. Br J Pharmacol. 2000 Dec;131(8):1503–1506. doi: 10.1038/sj.bjp.0703734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ligneau X., Morisset S., Tardivel-Lacombe J., Gbahou F., Ganellin C. R., Stark H., Schunack W., Schwartz J. C., Arrang J. M. Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol. 2000 Dec;131(7):1247–1250. doi: 10.1038/sj.bjp.0703712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moukil M. A., Veiga-da-Cunha M., Van Schaftingen E. Study of the regulatory properties of glucokinase by site-directed mutagenesis: conversion of glucokinase to an enzyme with high affinity for glucose. Diabetes. 2000 Feb;49(2):195–201. doi: 10.2337/diabetes.49.2.195. [DOI] [PubMed] [Google Scholar]
  14. Tramontano E., Colla P. L., Cheng Y. C. Biochemical characterization of the HIV-1 integrase 3'-processing activity and its inhibition by phosphorothioate oligonucleotides. Biochemistry. 1998 May 19;37(20):7237–7243. doi: 10.1021/bi972792o. [DOI] [PubMed] [Google Scholar]
  15. Wandel C., Kim R. B., Guengerich F. P., Wood A. J. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos. 2000 Aug;28(8):895–898. [PubMed] [Google Scholar]
  16. Zhu B. T., Patel U. K., Cai M. X., Conney A. H. O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase. Drug Metab Dispos. 2000 Sep;28(9):1024–1030. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES